Telmisartan in Haemodialysis Patients With Chronic Heart Failure

This study has been completed.
Information provided by:
Second University of Naples Identifier:
First received: June 22, 2007
Last updated: October 16, 2008
Last verified: November 2007

Background: In haemodialysis patients, chronic heart failure (CHF) is responsible for a high mortality rate but, presently, very little data is available regarding this population.

Aim of the study: Aim of this study was to determine whether telmisartan decreases all-cause and cardiovascular mortality and morbidity in haemodialysis patients with CHF and impaired left ventricular ejection fraction (LVEF) when added to standard therapies with ACE inhibitors.

Methods: A 3-year randomized, double-blind, placebo-controlled, multicentre trial was performed involving 30 Italian clinics. Haemodialysis patients with CHF (NYHA class II and III; LVEF 40%) were randomized to telmisartan or placebo in addition to ACE inhibitor therapy. 332 patients were enrolled (165 telmisartan, 167 placebo), and drug dosage was titrated to a target dose of telmisartan of 80 mg or placebo. Mean follow-up period was 35±5 months. Primary outcomes were all-cause mortality, cardiovascular mortality and CHF hospitalization.

Condition Intervention Phase
Heart Failure, Congestive
Drug: telmisartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effects Of Telmisartan Added To Angiotensin Converting Enzyme Inhibitors On Mortality And Morbidity In Haemodialysed Patients With Chronic Heart Failure: A Double-Blind Placebo-Controlled Trial

Resource links provided by NLM:

Further study details as provided by Second University of Naples:

Primary Outcome Measures:
  • all cause mortality cardiovascular mortality hospitalization for decompensated heart failure [ Time Frame: 36 months ]

Secondary Outcome Measures:
  • acute non-fatal myocardial infarction [ Time Frame: 36 months ]
  • combined endpoint (cardiovascular mortality in addition to acute non-fatal myocardial infarction) [ Time Frame: 36 months ]
  • cardiovascular hospital admission [ Time Frame: 36 months ]
  • nonfatal stroke [ Time Frame: 36 months ]
  • coronary revascularization [ Time Frame: 36 months ]
  • permanent premature treatment withdrawals [ Time Frame: 36 months ]

Enrollment: 351
Study Start Date: January 1999
Study Completion Date: June 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult haemodialysis patients with CHF;
  • New York Heart Association (NYHA) class II and III;
  • Ejection fraction less or equal to 40% determined within 6 months; and
  • Therapy with ACE inhibitors individually optimized and unchanged for 30 days before randomization

Exclusion Criteria:

  • Hypotension during dialysis;
  • Atrial fibrillation;
  • Intolerant to low dose of telmisartan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00490958

Chair of Cardiology Second University of Naples
Naples, Italy, 80100
Sponsors and Collaborators
Second University of Naples
Study Chair: Gennaro Cice, MD Chair of cardiology Second University of Naples
  More Information Identifier: NCT00490958     History of Changes
Other Study ID Numbers: tchf-01-01 
Study First Received: June 22, 2007
Last Updated: October 16, 2008
Health Authority: Italy: Ministry of Health

Keywords provided by Second University of Naples:
heart Failure
angiotensin converting enzyme inhibitor

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action
Protease Inhibitors processed this record on May 30, 2016